Immune system reset: CAR T-Cells take on autoimmune diseases
NCT ID NCT07161193
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe and can control the disease by targeting and destroying faulty immune cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19 CAR T-cells (a type of immune cell therapy)
What this could lead to
If successful, this could offer a new way to control severe autoimmune diseases that haven't responded to other treatments, potentially reducing symptoms and need for ongoing medications.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. There are serious risks like cytokine release syndrome and nerve toxicity, and it's unclear if the effects will last without continued treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Luoyang, Henan, 471003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Contact
Contact